ClinicalTrials.gg
RecruitingNCT06190366Updated Jan 5, 2024

Effects of Bloodletting Acupuncture for Subacute and Chronic Non-specific Low Back Pain

An interventional study of Bloodletting acupuncture at the fossa poplitea and Bloodletting acupuncture at the regio glutaea in Back Pain, Low, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Low Back Pain with a site in Germany — 5 open to participants now, 8 under way, 3 of them phase 3. Low Back Pain · Germany.

Planned enrollment
32nd of 54
108 · median 128
Started
2023
with 7 others
No phase
31 of 59
3 open now
Registered
54th of 59
by date
Lead sponsor
9 of 59
Charite University, Berlin, Germany

Among the 59 studies in Low Back Pain with a site in Germany, this one is the 32nd largest by planned enrollment of the 54 interventional ones that give a count, is one of 8 that started in 2023, is one of 31 with no phase, and was the 54th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

5 of the 59 studies in Low Back Pain with a site in Germany are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Low Back Pain with a site in Germany, or all of them as a file.
02

Study summary

Evaluation of a bloodletting acupuncture at the fossa poplitea in comparison to bloodletting acupuncture at the regio glutaea and a waiting list control group in patients with subacute and chronic non-specific pain low back pain.

03

Conditions studied

  • Back Pain, Low

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Specialist confirmed diagnosis of subacute or chronic non-specific low back pain for at least 6 weeks prior to inclusion
  • Average pain intensity with at least 50 mm on the VAS from 0 to 100 mm

Exclusion criteria

Exclusion criteria:

  • Serious illnesses
  • Poor general condition
  • Coagulation disorder, therapy with anticoagulants
  • Thrombophlebitis, skin inflammation in the area of the lower extremities
  • Alcohol, drug or medication addiction
  • Pregnancy
  • Lack of willingness to cooperate, linguistically or mentally unable to understand the contents of the study
  • Participation in another clinical trial during the study period
  • Starting a new therapy for the treatment of low back pain in the last 2 weeks
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Bloodletting acupuncture at the fossa poplitea

    Procedure: Bloodletting acupuncture at the fossa poplitea

  • Experimental
    Bloodletting acupuncture at the regio glutaea

    Procedure: Bloodletting acupuncture at the regio glutaea

  • No intervention
    Waiting list control group

Interventions

  • ProcedureBloodletting acupuncture at the fossa poplitea

    This group is treated with bloodletting acupuncture at the fossa poplitea. The treatment takes place twice a week from week 1 to week 3. This means that 6 treatments of approx. 20 minutes each should be carried out within the 3 weeks.

  • ProcedureBloodletting acupuncture at the regio glutaea

    This group is treated with bloodletting acupuncture at the regio glutaea. The treatment takes place twice a week from week 1 to week 3. This means that 6 treatments of approx. 20 minutes each should be carried out within the 3 weeks.

06

What researchers measure

Primary outcomes

  1. Change from baseline in average pain intensity in previous week

    Intensity of pain in previous week as measured on a 100 mm visual analog scale (0-100).

    Time frame: Baseline, 3 weeks

Secondary outcomes

  1. Change from baseline in average pain intensity in previous week

    Intensity of pain in previous week as measured on a 100 mm visual analog scale (0-100).

    Time frame: Baseline, 6 weeks

  2. Change from baseline in average pain intensity of the last 24 hours

    Intensity of pain in previous week as measured on a 100 mm visual analog scale (0-100).

    Time frame: Baseline, 3 weeks, 6 weeks

  3. Change from baseline for back pain specific disability

    Use of standardized Roland Morris Disability Questionnaire (RMDQ) to assess back pain specific disability. The scale ranges from 0 to 100, where 0 is the lowest level and 100 is the highest level.

    Time frame: Baseline, 3 weeks, 6 weeks

  4. Change from baseline in pain bothersomeness in previous week

    Bothersomeness in previous week as measured on a 100 mm visual analog scale (0-100).

    Time frame: Baseline, 3 weeks, 6 weeks

  5. Change from baseline for days with pain medication use

    Specific self-reported pain medication use

    Time frame: Baseline, 3 weeks, 6 weeks

  6. Change from baseline for health related quality of life

    Use of standardized Short Form 36 Health Survey (SF-36). The scale ranges from 0 to 100, where 0 is the lowest level and 100 is the highest level.

    Time frame: Baseline, 3 weeks, 6 weeks

  7. Change from baseline for pain self-efficacy

    Use of standardized Pain Self-Efficacy Questionnaire (PSEQ). The scale ranges from 0 to 100, where 0 is the lowest level and 100 is the highest level.

    Time frame: Baseline, 3 weeks, 6 weeks

  8. Change from baseline for anxiety and depression

    Use of standardized Hospital Anxiety and Depression Scale (HADS). The scale ranges from 0 to 100, where 0 is the lowest level and 100 is the highest level.

    Time frame: Baseline, 3 weeks, 6 weeks

  9. Change from baseline for work productivity

    Use standardized Work Productivity and Activity Impairment Questionnaire (WPAI) to assess employment status and productivity. The scale ranges from 0 to 100, where 0 is the lowest level and 100 is the highest level.

    Time frame: Baseline, 3 weeks, 6 weeks

Other outcomes

  1. Number of participants with adverse events as a measure of safety and treatment adherence

    Identify and assess self reported and unanticipated adverse events over the course of the study as a measure of safety and treatment adherence.

    Time frame: 3 weeks, 6 weeks

  2. Treatment adherence

    Assess treatment adherence according to attendance during 3 week intervention period.

    Time frame: 3 weeks

  3. Treatment expectation: effectiveness of bloodletting acupuncture in reducing low back pain

    Assess treatment expectation at baseline, Likert scale (1-very good effectiveness to 5-poor effectiveness)

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Charité Hochschulambulanz für Naturheilkunde, Immanuel Krankenhaus Berlin
    Berlin, 14163, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2024, 12 months after the start.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 12 months is close to that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Jan 5, 2024
StartActual
Dec 19, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2025
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06190366
Responsible party
Andreas Michalsen (Principal Investigator, Charite University, Berlin, Germany) — Principal investigator
First posted
Jan 5, 2024
Start date
Dec 19, 2023
Primary completion
Dec 2024 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jan 5, 2024

Study contacts

Miriam Rösner
Contact
naturheilkunde.studien@immanuel.de
+49 30 80505 682

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion